Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.
Gynecol Oncol. 2021 Jan;160(1):199-205. doi: 10.1016/j.ygyno.2020.10.041. Epub 2020 Nov 9.
Oncologic treatment has been associated with unemployment. As endometrial cancer is highly curable, it is important to assess whether patients experience employment disruption after treatment. We evaluated the frequency of employment change following endometrial cancer diagnosis and assessed factors associated with it.
A cohort of patients 18-63 years-old who were diagnosed with endometrial cancer (January 2009-December 2017) were identified in the Truven MarketScan database, an insurance claims database of commercially insured patients in the United States. All patients who were working full- or part-time at diagnosis were included and all employment changes during the year following diagnosis were identified. Clinical information, including use of chemotherapy and radiation, were identified using Common Procedural Terminology codes, and International Statistical Classification of Diseases codes. Cox proportional hazards models incorporating measured covariates were used to evaluate the impact of treatment and demographic variables on change in employment status.
A total of 4381 women diagnosed with endometrial cancer who held a full-time or part-time job 12 months prior to diagnosis were identified. Median age at diagnosis was 55 and a minority of patients received adjuvant therapy; 7.9% received chemotherapy, 4.9% received external-beam radiation therapy, and 4.1% received chemoradiation. While most women continued to work following diagnosis, 21.7% (950) experienced a change in employment status. The majority (97.7%) of patients had a full-time job prior to diagnosis. In a multivariable analysis controlling for age, region of residence, comorbidities, insurance plan type and presence of adverse events, chemoradiation recipients were 34% more likely to experience an employment change (HR 1.34, 95% CI 1.01-1.78), compared to those who only underwent surgery.
Approximately 22% of women with employer-subsidized health insurance experienced a change in employment status following the diagnosis of endometrial cancer, an often-curable disease. Chemoradiation was an independent predictor of change in employment.
肿瘤治疗与失业有关。由于子宫内膜癌的治愈率很高,因此评估治疗后患者是否会失业非常重要。我们评估了诊断为子宫内膜癌后就业变化的频率,并评估了与之相关的因素。
在 Truven MarketScan 数据库(美国商业保险患者的保险索赔数据库)中确定了 2009 年 1 月至 2017 年 12 月期间诊断为子宫内膜癌的 18-63 岁患者队列。所有在诊断时全职或兼职工作的患者均包括在内,并确定了诊断后一年内的所有就业变化。使用常见程序术语代码和国际疾病分类代码确定临床信息,包括化疗和放疗的使用。使用包含测量协变量的 Cox 比例风险模型来评估治疗和人口统计学变量对就业状况变化的影响。
共确定了 4381 名在诊断前 12 个月全职或兼职工作的诊断为子宫内膜癌的女性。诊断时的中位年龄为 55 岁,少数患者接受了辅助治疗;7.9%接受化疗,4.9%接受外照射放疗,4.1%接受放化疗。尽管大多数女性在诊断后继续工作,但仍有 21.7%(950 人)的就业状况发生变化。在诊断前,大多数(97.7%)患者有全职工作。在多变量分析中,控制年龄、居住地区、合并症、保险计划类型和不良事件的存在,与仅接受手术的患者相比,接受放化疗的患者发生就业变化的可能性高 34%(HR 1.34,95%CI 1.01-1.78)。
约 22%的雇主资助医疗保险的女性在诊断为子宫内膜癌后就业状况发生变化,而子宫内膜癌是一种常可治愈的疾病。放化疗是就业变化的独立预测因素。